Results 21 to 30 of about 28,620 (235)

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS [PDF]

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj   +1 more source

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients. [PDF]

Clin Pharmacol Ther
Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real‐life studies show a high degree of genotype–phenotype mismatch in escitalopram metabolism.
Hole K, Wollmann BM, Stingl JC, Molden E.   +3 more
europepmc   +2 more sources

The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping [PDF]

Pharmacogenetics and Genomics, 2014
The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp upstream the CYP2C19*2 SNP.
Taimour Y, Langaee, Hao-Jie, Zhu, Xinwen, Wang, Nihal, El Rouby, John S, Markowitz, Joyce A, Goldstein, Julie A, Johnson   +6 more
openaire   +3 more sources

PharmVar GeneFocus: CYP2C19 [PDF]

Clinical Pharmacology & Therapeutics, 2020
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications.
Botton, Mariana R., Whirl-Carrillo, Michelle, Del Tredici, Andria L., Sangkuhl, Katrin, Cavallari, Larisa H., Agúndez, José A., Duconge, Jorge, Lee, Ming Ta Michael, Woodahl, Erica L., Claudio-Campos, Karla, Daly, Ann K., Klein, Teri E., Pratt, Victoria M., Scott, Stuart A., Gaedigk, Andrea   +14 more
openaire   +2 more sources

The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population [PDF]

, 2023
Acces full text - https://doi.org/10.1007/978-3-031-42782-4_42Genetic polymorphisms of drug-metabolizing enzymes, such as cytochrome P450 oxidases, can alter the pharmacokinetic properties of administered drugs, leading to variability in drug responses ...
CUROCICHIN, Ghenadie, GALEA-ABDUSA, Daniela, CAPROS, Natalia, BUZA, Anastasia, DOGOT, Marta   +4 more
core   +1 more source

Stereoselective Determination of Omeprazole and 5-Hydroxy-Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT We previously proposed stereoselective 5‐hydroxy‐omeprazole/omeprazole cut‐offs for R‐ and S‐omeprazole to differentiate between rapid, normal, and poor CYP2C19 metabolisers. However, the performance of these stereoselective CYP2C19 phenotyping approaches has never been compared with conventional racemic omeprazole phenotyping.
Hectors T, Abouir K, Varesio E, Manson ML, Daali Y, Samer C.   +5 more
europepmc   +2 more sources

CYP2C19

, 2022
This data includes the sequencing of the three SNP loci of the CYP2C19 ...
Liping Liu (12599533)
core   +1 more source

A Phase 1 Study of MK-1942, a Negative Allosteric Modulator of mGluR2, in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype. [PDF]

Clin Transl Sci
ABSTRACT MK‐1942 is a negative allosteric modulator of the metabotropic glutamate receptor 2 that was investigated for the treatment of Alzheimer's disease and depression. Nonclinical studies with recombinant human CYPs and genotyped human hepatocytes suggested that CYP2C19 is involved in the metabolism of MK‐1942. Given the high incidence of different
Hasegawa C, Doi Y, Hirano T, Shirakawa M, Tsuchiya S, Yoshitsugu H, Furihata K, Miller C, Singh S, Cabalu T, Yee KL, Bueters T, Alexopoulou Z.   +12 more
europepmc   +2 more sources

CYP2C19 variation and citalopram response [PDF]

Pharmacogenetics and Genomics, 2011
Variations in cytochrome P450 (CYP) genes have been shown to be associated with both accelerated and delayed pharmacokinetic clearance of many psychotropic medications. Citalopram is metabolized by three CYP enzymes. CYP2C19 and CYP3A4 play a primary role in citalopram metabolism, whereas CYP2D6 plays a secondary role.The Sequenced Treatment ...
David A, Mrazek, Joanna M, Biernacka, Dennis J, O'Kane, John L, Black, Julie M, Cunningham, Maureen S, Drews, Karen A, Snyder, Susanna R, Stevens, Augustus John, Rush, Richard M, Weinshilboum   +9 more
openaire   +2 more sources

Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group

Oman Medical Journal, 2013
Objective: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study
Robabeh Ghiyas Tabari, Abdoljalal Marjani, Ogholdondy Agh Ataby, Azad Reza Mansourian, Nader Mansour Samai   +4 more
doaj   +1 more source